MacroGenics - MGNX Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings or view top-rated stocks.

10 brokers have issued 1-year price objectives for MacroGenics' stock. Their MGNX share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $9.56 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price.
View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts.

MacroGenics' stock was trading at $6.71 at the start of the year. Since then, MGNX shares have decreased by 16.7% and is now trading at $5.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MGNX earnings forecast.

MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.23. The biopharmaceutical company had revenue of $15.66 million for the quarter, compared to analysts' expectations of $39.56 million. MacroGenics had a negative trailing twelve-month return on equity of 111.57% and a negative net margin of 204.95%. During the same quarter in the prior year, the company earned ($0.66) EPS.

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (2.43%), Pinnacle Associates Ltd. (0.60%), Pinnacle Associates Ltd. (0.60%), Hennion & Walsh Asset Management Inc. (0.06%), New York State Common Retirement Fund (0.06%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGNX stock can currently be purchased for approximately $5.59.

MacroGenics (NASDAQ:MGNX) has a market capitalization of $343.65 million and generates $91.19 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

The company employs 427 workers across the globe.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.